"Indirect" DTC of Rx drug claimed by UK's ASA

23 February 2009

The UK's Advertising Standards Authority, which has the power to ban individual promotional campaigns, has declared that an Australian  clinic's London subsidiary offering treatment for male erectile  dysfunction was "indirectly advertising a prescription-only medicine," a  finding disputed by the Advanced Medical Institute, which plans to lodge  an appeal.

The ASA received 522 complaints against billboard posters that appear to  have been largely based on the presence of the word "sex" in the  advertisement text. The Authority noted that this number would likely  have been higher if it had not imposed a ban before conducting its  investigation of the AMI's message.

Michael Spira, the firm's European chief medical officer, claimed that,  "whilst the ASA has ruled that the advertisements promote  prescription-only medication by using the phrase 'nasal delivery  technology,' we believe that this ruling is not supported by the wording  of the ASA's code."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight